Real-world use of diagnostic tests for mild cognitive impairment, Alzheimer's disease, and other dementias in Medicare fee-for-service beneficiaries.

Introduction: This study assessed real-world use of diagnostic tests, such as neuroimaging (e.g., magnetic resonance imaging [MRI], or positron emission tomography [PET]), and computed tomography (CT), cerebrospinal fluid (CSF) biomarker, and blood tests for mild cognitive impairment (MCI), Alzheimer's disease (AD), and other dementias in a large US elderly population.